Traws Pharma, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|
| Revenue | $787.0K | $5.5M | $11.5M | $800.0K | $4.8M | $46.2M | $1.5M |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $19.1M | $20.1M | $25.9M | $49.4M | $50.2M | $52.8M | $22.6M |
| SG&A Expense | $7.4M | $9.2M | $9.5M | $15.1M | $16.8M | $15.7M | $6.4M |
| Operating Income | $-25.7M | $-23.7M | $-24.0M | $-63.7M | $-62.2M | $-22.3M | $-27.6M |
| Operating Margin | -3,270.3% | -427.4% | -209.3% | -7,968.0% | -1,309.1% | -48.2% | -1,854.3% |
| Interest Expense | — | — | — | $2.0K | $4.0K | $8.6M | $19.0K |
| Pretax Income | $-24.1M | $-19.7M | $-24.0M | $-63.8M | $-62.1M | $-29.9M | $-26.3M |
| Income Tax Expense | $13.0K | $14.0K | $16.0K | $19.0K | $435.0K | — | — |
| Net Income | $-24.1M | $-19.7M | $-24.0M | $-63.7M | $-62.5M | $-29.9M | $-26.3M |
| Net Margin | -3,061.2% | -354.6% | -209.3% | -7,960.3% | -1,315.9% | -64.8% | -1,768.3% |
| EPS (Basic) | $-8.03 | $-0.89 | $-2.11 | $-0.59 | $-1.22 | $-3.07 | $-2.84 |
| EPS (Diluted) | $-8.03 | $-0.89 | $-2.11 | $-0.59 | $-1.22 | $-3.07 | $-2.84 |
| Shares Outstanding (Basic) | 3.6M | 33.8M | 12.7M | 108.5M | 107.3M | 13.0M | — |
| Shares Outstanding (Diluted) | 3.6M | 33.8M | 12.7M | 108.5M | 107.3M | 13.0M | — |
| Dividends Per Share | — | — | — | — | — | — | — |